A Phase 1 interventional study of EDP167 and Placebo in Healthy Adult Male and Female Volunteers and Mild Dyslipidemia, sponsored by Eddingpharm (Zhuhai) Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Eddingpharm (Zhuhai) Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Dyslipidemias with a site in China — 21 open to participants now, 31 under way, 10 of them phase 3. Dyslipidemias · China.
Among the 73 studies in Dyslipidemias with a site in China, this one is the 50th largest by enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2025, is one of 6 in phase 1, and was the 64th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →21 of the 73 studies in Dyslipidemias with a site in China are open now. Recruiting first, the newest first:
Shanghai Minwei Biotechnology Co., Ltd · Sites in China
Ages 18–75
China Medical University, China · Sites in China
Ages 50–75
Peking University Third Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Eddingpharm (Zhuhai) Co., Ltd. · Sites in China
Ages 18+
First Affiliated Hospital of Fujian Medical University · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 17 · Phase 4 12
First in 2008; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 213 across the 56 interventional studies, 1,000 across the 17 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 73 have an industry lead sponsor. The 10 most frequent:
Eddingpharm (Zhuhai) Co., Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Eddingpharm (Zhuhai) Co., Ltd. has 3 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
8 of the studies in Dyslipidemias with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07350486First Hospital of China Medical UniversityLLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Dyslipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.
Angiopoietin-like 3 protein (ANGPTL3) is a key regulator of lipid metabolism. Clinical studies have shown that inhibition of ANGPTL3 could exert lipid-lowering effects in patients with dyslipidemia. EDP167 is a novel GalNAc-conjugated siRNA therapeutic that selectively silences hepatic ANGPTL3 mRNA expression, offering a promising strategy for lipid lowering. In this trial, subjects will be sequentially enrolled into five cohorts (35, 100, 200, 300 or 400 mg), each consists of six subjects receiving EDP167 and two receiving matching placebos. The follow-up will last for 85 days to evaluate the PK profile and PD effects (ANGPTL3, LDL-C, TG, and other lipid parameters) following a single subcutaneous injection of EDP167.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EDP167 35mg (N=6) and Placebo (N=2)
Drug: EDP167 · Drug: Placebo
EDP167 100mg (N=6) and Placebo (N=2)
Drug: EDP167 · Drug: Placebo
EDP167 200mg (N=6) and Placebo (N=2)
Drug: EDP167 · Drug: Placebo
EDP167 300mg (N=6) and Placebo (N=2)
Drug: EDP167 · Drug: Placebo
EDP167 400mg (N=6) and Placebo (N=2)
Drug: EDP167 · Drug: Placebo
EDP167 sc injection
Sterile normal saline (0.9% NaCl) sc injection
To evaluate the safety and tolerability of a single subcutaneous injection of EDP167 in adult subjects.
Number of participants with adverse events and serious adverse events, with clinically significant changes in vital signs, in electrocardiogram readings, in physical examination, and in laboratory tests.
Time frame: Up to 85 days post-dose
To evaluate the plasma concentration-time area under curve (AUC) of a single subcutaneous injection of EDP167 in adult subjects.
Concentration-time area under curve (AUC) of EDP167 in plasma
Time frame: Up to 48 hours post-dose
To evaluate the time to peak concentration (Tmax) of a single subcutaneous injection of EDP167 in adult subjects.
Time to peak concentration (Tmax) of EDP167 in plasma
Time frame: Up to 48 hours post-dose
To evaluate the peak concentration (Cmax) of a single subcutaneous injection of EDP167 in adult subjects.
Peak concentration (Cmax) of EDP167 in plasma
Time frame: Up to 48 hours post-dose
To evaluate the apparent volume of distribution (Vd) of a single subcutaneous injection of EDP167 in adult subjects.
Time frame: Up to 48 hours post-dose
To evaluate the clearance (CL) of a single subcutaneous injection of EDP167 in adult subjects.
Time frame: Up to 48 hours post-dose
To evaluate the elimination half-time (t1/2) of a single subcutaneous injection of EDP167 in adult subjects.
Time frame: Up to 48 hours post-dose
To evaluate the pharmacodynamic characteristics (ANGPTL3) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum ANGPTL3 level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (TG) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum TG level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (LDL-C) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum LDL-C level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (TC) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum TC level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (non-HDL-C) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum non-HDL-C level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (VLDL-C) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum VLDL-C level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (HDL-C) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum HDL-C level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (Lp(a)) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum Lp(a) level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (ApoB) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum ApoB level.
Time frame: Up to 85 days post-dose
To evaluate the pharmacodynamic characteristics (ApoA-I) of a single subcutaneous injection of EDP167 in adult subjects.
Change from baseline in fasting serum ApoA-I level.
Time frame: Up to 85 days post-dose
The effect of EDP167 injection on QT interval evaluated by C-QT analysis.
The difference from baseline of QTcF after administration.
Time frame: Up to 48 hours post-dose
The effect of EDP167 injection on QT interval evaluated by C-QT analysis.
The correlation between drug serum concentration and QTcF.
Time frame: Up to 48 hours post-dose
To evaluate the immunogenicity of EDP167.
The incidence and titer of antibodies against EDP167.
Time frame: Up to 85 days post-dose
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 5 months is above that.
Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP167
Eddingpharm (Zhuhai) Co., Ltd.